MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma – Nasdaq

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma  Nasdaq

LA JOLLA, Calif., April 23, 2019– MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the.